A randomized trial of amifostine as a cytoprotective agent in patients receiving chemotherapy for small cell lung cancer

British Journal of Cancer

Volumn 84, Issue 1, 2001, Pages 19-24

  Johnson, P W M ^a   Muers, M F ^b   Peake, M D ^c   Poulter, K M ^d   Gurney, E M ^d   Napp, V ^d   Hepburn, P M ^d   Brown, J M ^d  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^b LEEDS GENERAL INFIRMARY   (United Kingdom)

^c Pontefract General Infirmary   (United Kingdom)

^d Northern and Yorkshire Clinical Trials and Research Unit   (United Kingdom)

Author keywords

Amifostine; Chemoprotection; Chemotherapy; Myelotoxicity; Small cell lung cancer; Survival

Indexed keywords

AMIFOSTINE; CARBOPLATIN; ETOPOSIDE; IFOSFAMIDE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CELL PROTECTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; LUNG SMALL CELL CANCER; MALE; NEUTROPENIA; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA;

ADULT; AGED; AMIFOSTINE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, SMALL CELL; DRUG ADMINISTRATION SCHEDULE; ETOPOSIDE; FEMALE; HUMANS; IFOSFAMIDE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEUTROPENIA; SURVIVAL ANALYSIS; THROMBOCYTOPENIA;

EID: 0035139187     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1054/bjoc.2000.1539     Document Type: Article

References (13)

1. A randomized trial of cyclophosphamide and cisplatin + WR-2721 in the treatment of advanced epithelial ovarian cancer
2. WR-2721 protects against the hematologic toxicity of cyclophosphamide: A controlled phase II trial
3. Nonparametric estimation from incomplete observations
4. Received dose-intensity: A randomized trial of weekly chemotherapy with and without granulocyte colony-stimulating factor in small-cell lung cancer
5. Therapy for small cell lung cancer using carboplatin, ifosfamide, etoposide (without dose reduction), mid-cycle vincristine with thoracic and cranial irradiation
6. Randomized study of cyclophosphamide plus doxorubicin plus vincristine versus etoposide plus cisplatin versus alternation of these two regimens in extensive small cell lung cancer: A phase III trial of the Southwestern Oncology Group
7. Modified ice study: A phase II study of an intensive, modified ICE regimen (ifosfamide, carboplatin and etoposide) in patients with better prognosis, small cell lung cancer
8. Longevity in small cell lung cancer. A report to the Lung Cancer Subcommittee of the United Kingdom Coordinating Committee for Cancer Research
9. Effects of granulocyte-macrophage colony-stimulating factor and dose intensification of V-ICE chemotherapy in small-cell lung cancer: A prospective randomized study of 300 patients
10. Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colony-stimulating factor support: Results of a British Medical Research Council Multicenter Randomized Trial. Medical Research Council Lung Cancer Working Party
11. Protection of normal tissues from the cytotoxic effects of chemotherapy and radiation by amifostine (ethyol): Preclinical aspects
12. Active versus passive absorption kinetics as the basis for selective protection of normal tissues by S-2-(3-aminopropylamino)-ethylphosphorothioic acid